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Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by an exacerbated fibrotic response. Althoughmolecular
and cellular determinants involved in the onset and progression of this devastating disease are largely unknown, an aberrant
remodeling of the pulmonary vasculature appears to have implications in IPF pathogenesis. Here, we demonstrated for the first
time that an increase of reactive oxygen species (ROS) generation induced by sera from IPF patients drives both collagen type I
deposition and proliferation of primary human pulmonary artery smooth muscle cells (HPASMCs). IPF sera-induced cellular
effects were significantly blunted in cells exposed to the NADPH oxidase inhibitor diphenyleneiodonium (DPI) proving the
causative role of ROS and suggesting their potential cellular source. Contrary to IPF naive patients, sera from Pirfenidone-
treated IPF patients failed to significantly induce both ROS generation and collagen synthesis in HPASMCs, mechanistically
implicating antioxidant properties as the basis for the in vivo effect of this drug.
1. Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive
lung disease characterized by an abnormal fibrotic response
involving several areas of the lung tissue [1]. An aberrant tis-
sue structure, encompassing exacerbated collagen secretion
and deposition, progressively replaces the healthy tissue
architecture, dramatically compromising the lung functions
and ultimately leading to death [2]. The molecular and cellu-
lar determinants that trigger and maintain these processes
are largely unknown. However, it seems that repetitive
microinjuries directed towards the alveolar epithelium may
play a major role [2]. Indeed, the abovementioned process
leads to the release of different growth factors and fibrotic
mediators such as fibroblast growth factor (FGF), platelet-
derived growth factor (PDGF), and transforming growth
factor-beta 1 (TGF-β1), which activate myofibroblast recruit-
ment, proliferation, and accumulation of extracellular matrix
in alveolar regions [2].
Although the fibroblast appears to be the most well
established, other types of cells have been reported to be
implicated in the IPF-associated fibrotic process [2]. In
addition to a destroyed parenchyma [2], an aberrant
microvascular and macrovascular remodeling of the pul-
monary vasculature appears to be strongly implicated in
IPF pathogenesis [3]. In this context, vascular smooth
muscle cells (VSMCs) play a pivotal role in maintaining
organ and tissue physiological remodeling. Indeed, under
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physiological conditions, the contractile phenotype of
VSMCs is actively involved in the control of organ micro-
circulation, architecture, and function [4]. However, when
a vascular injury occurs in response to proinflammatory
factors, VSMCs undergo a “phenotypic switch” that con-
fers in them the ability to proliferate, migrate, and synthe-
size extracellular matrix, ultimately leading to a dramatic
pathological restructuring of the involved tissue [4]. Despite
the massive vascular remodeling associated to IPF [3], and
the potential implication of VSMCs in this process [5, 6],
their role in the onset and progression of IPF-associated
fibrotic phenomena remains to be elucidated. For example,
whether VSMCs are involved in IPF-associated vascular
remodeling in terms of increased proliferation and collagen
deposition has never been investigated.
After decades of having no effective medical treatment
for IPF, two recent antifibrotic agents have been introduced
for the management of this pathology: Nintedanib, a potent
kinase inhibitor blocking the effects of growth factors impli-
cated in the pathogenesis of IPF (platelet-derived growth fac-
tor, vascular endothelial growth factor, and fibroblast growth
factor) [7], and Pirfenidone, whose mechanisms of action are
still unclear [8]. However, with Pirfenidone, some papers
suggest that this molecule possesses antioxidant properties,
which might account for its reported antifibrotic effect as
evidenced in experimental models of lung fibrosis [9, 10].
Oxidative stress has been previously linked to IPF at both
the systemic and tissue levels [11–14]. In particular, NOX-4,
a ROS-generating enzyme member of the NADPH family
has been reportedly implicated in IPF-associated vascular
remodeling [15].
We hypothesized that prooxidant circulating factors
may trigger VSMCs’ phenotypic switching and induce cell
proliferation and collagen I synthesis and that the antioxi-
dant properties of Pirfenidone can counteract this pheno-
typic change and thus ameliorate IPF patients’ conditions.
To verify our two research questions, we investigated reactive
oxygen species (ROS) production, cell proliferation, and col-
lagen synthesis in primary human vascular smooth muscle
cells exposed to serum obtained from naive IPF patients
(IPF) or IPF patients treated with Pirfenidone (IPF+D)
and healthy donors (HD).
2. Materials and Methods
2.1. Patients. IPF was diagnosticated in accordance with
evidence-based guidelines for the diagnosis and management
of IPF [16]. High-resolution computed tomography (HRCT)
images and lung-biopsy specimens of the enrolled patients
were reviewed in our hospital by two experienced radiologists
and two experienced pathologists, respectively, to verify eligi-
bility. The diagnosis for each enrolled case was approved
based on a multidisciplinary discussion of experienced inter-
stitial lung disease experts in the respiratory, pathology, and
radiology departments of the University of Sassari. The eligi-
ble patients were 11.72% of the sample and had a diagnosis of
consistent IPF based on the radiological pattern of usual
interstitial pneumonia (UIP) on computed tomography
(CT) scan, while 38% of the sample had a possible UIP pat-
tern on CT scan; therefore, the latter was submitted to an
awake surgical biopsy that showed a histological UIP pattern.
In addition to the diagnosis of IPF, all enrolled cases met the
following lung function criteria: percentage of predicted
forced vital capacity (FVC) of at least 50% and percentage
of predicted carbon monoxide diffusing capacity (DLCO)
of at least 35%. All patients were treated with Pirfenidone
2403mg/day according to the ATS ERS IPF treatment
guideline [17]. Completion of a 24-week treatment period
was followed by a follow-up visit 2 weeks later. Spirometry
testing was performed in accordance with the criteria pub-
lished by the American Thoracic Society and the European
Respiratory Society [18] at baseline and after 24weeks of
treatment Table 1.
Patients with the following conditions were excluded
from the study: currently in a period of acute exacerbation
of IPF; comorbid conditions including malignancy, bleeding
tendency, and severe hepatic dysfunction (alanine transami-
nase or aspartate transaminase level two-fold above the
upper limit of normal, or renal serum creatinine level above
the upper limit of normal); use of immunosuppressants, anti-
fibrotic drugs including interferon, D-penicillamine, and col-
chicine, or oral corticosteroids at a dose≥ 15mg/day or the
equivalent during the preceding 3 months; and current preg-
nancy or breastfeeding. All enrolled patients provided writ-
ten informed consent, and the protocol for our study was
Table 1: Patient demographics and clinical characteristics.
Subjects characteristics PT0, n = 11 PT1, n = 11 HD, n = 11 P value
Age, years, mean (SD) 71.27 (5.51) 71.27 (5.51) 67.0 (9.4) P = 0 21∗
Male, n (%) 8 (72.72) 8 (72.72) 9 (81.81) P = 0 62#
Former smokers, n (%) 9 (81.8) 9 (81.8) 8 (72.72) P = 0 62#
FVC, ml, mean (SD) 2343.6 (777.88) 2385.45 (801.51) 0.6328§
FVC, % predicted, mean (SD) 81.04 (26.95) 77.90 (24.49) 0.1813§
FEV1/FVC ratio, %, mean (SD) 92.81 (4.43) 91.66 (6.66) 0.7161
§
DLCO, % predicted, mean (SD) 54.17 (18.11) 56.1 (22.38) 0.5770§
PT0, Pirfenidone T0, which refers to untreated patients just diagnosticated with IPF; PT1, Pirfenidone T1, which refers to IPF patients treated with
Pirfenidone for 24 weeks; HD, healthy donors, which refers to healthy blood donors; FVC, forced vital capacity; FEV1, forced expiratory volume1; DLCO,
carbon monoxide diffusing lung capacity. §P values were determined by paired t-test (PT0 versus PT1), ∗unpaired t-test (HD versus PT0/PT1), and
#Chi-square (HD versus PT0/PT1).
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approved by the ethics committee of the University Hospital
of the University of Sassari (2262/CE-17/11/2015). Age- and
sex-matched healthy donors were recruited through posted
flyers and enrolled after passing a screening questionnaire
aimed at excluding the presence of any underlying vascular
or autoimmune disease. Blood samples were collected at the
time of the IPF diagnosis and after 24weeks of Pirfenidone
treatments, and then sera were prepared according to our
previously published procedures [19].
2.2. Cell Culture. In this study, pulmonary artery smooth
muscle cells (HPASMCs) isolated from human pulmonary
arteries of healthy donors were used (Innoprot, Spain).
Cells were cultured in HPASMC basal medium supple-
mented with endothelial cell growth supplement. When con-
fluent, HPASMCs were subcultured at a split ratio of 1 : 2 and
used within three passages. Unless not specified in the text,
cells were plated in 96-well black plates (BD Falcon) and
processed for experiments in basal medium containing
10% (v/v) of the subjects’ sera. Sera among the different sub-
jects were normalized based on protein content. To investi-
gate the involvement of NADPH oxidase in the IPF sera-
induced cellular effects, in selected experiments, cells were
pretreated for 1 hr with 10μM of the flavin-oxidase inhibitor
diphenyleneiodonium (DPI) [20, 21].
2.3. Determination of Intracellular ROS Levels. Intracellular
ROS levels were assessed by using the ROS molecular
probe 2′,7′-dichlorodihydrofluorescein diacetate (H2DCF-
DA) (Molecular Probes) as previously described [22, 23].
Within the cell, esterases cleave the acetate groups on
H2DCF-DA, thus trapping the reduced form of the probe
(H2DCF). Intracellular ROS oxidize H2DCF, yielding the
fluorescent product, DCF. For ROS measurements, cultured
cells were preincubated for 30min with PBS plus containing
1μM H2DCFDA, then washed with PBS and treated as
described. Fluorescence was measured by using a Tecan
GENios Plus microplate reader (Tecan, Switzerland) in a
light-protected condition. Excitation and emission wave-
lengths used for fluorescence quantification were 485nm
and 535nm, respectively. Treatment-induced variation of
fluorescence was kinetically measured over a time-course of
5 hours. All fluorescence measurements were corrected for
background fluorescence and protein concentration. Using
untreated cells as a reference, the anti- and prooxidant out-
comes were evaluated by the comparison of five measure-
ments and expressed as a means± SD of the relative
fluorescence unit (RFU) values.
2.4. Determination of Collagen Type I Synthesis.As previously
described, collagen type-I (COLS) synthesis was investigated
employing COL1A1-LV-tGFP, a GFP-based lentiviral vector
(LV) driven by the human COL1A1 gene promoter [22, 24].
A red fluorescence protein-based LV (EF1α-LV-FP602) was
used to normalize the cell transduction efficiency [22]. This
method allows us to perform the real-time assessment of
multiple samples at the same time in a 96-well plate using a
small amount of subject sera [22]. HPMECs were transduced
with lentiviral particles obtained from the pCOL1A1-LV-
tGFP and EFα-LV-FP602 lentivectors. Transduction effi-
ciency was checked and confirmed under a fluorescence
microscope. Treatment-induced variation of fluorescence
was kinetically measured over a time-course of 12 hours
using a Tecan GENios Plus microplate reader (Tecan,
Switzerland). Excitation wavelengths used for fluorescence
quantification were 485nm and 535nm, while emission
wavelengths were 535nm and 590 nm for pCOL1A1-LV-
tGFP and EFα-LV-FP602, respectively. Data were normal-
ized for transduction efficiency by reporting the ratio of
pCOL1A1-LV-tGFP to EFα-LV-FP602 and expressed as a
means± SD of the relative fluorescence unit (RFU) values.
2.5. Determination of Collagen Type I Protein Levels. Varia-
tion of collagen synthesis in response to sera treatment was
quantitatively confirmed by assessing the collagen protein
levels (COLP) with an enzyme immunoassay kit (Takara
Bio Inc., cat. number MK101) following the protocol pro-
vided by the manufacturer. Briefly, after 48 h sera treatment
cells were washed and recovered in the protein extraction
buffer. 100μl of peroxidase-labeled anticollagen monoclonal
antibody solution was transferred into each well for an antic-
ollagen monoclonal antibody coating. Subsequently, 20μl of
cell extract (samples were normalized for protein content)
or standard was added. Then, the solution was incubated
for 3 hours at 37°C. Then, 100μl of substrate solution was
added into each well. The reaction between a peroxidase-
labeled anticollagen monoclonal antibody and substrate
results in color development with intensities proportional
to the amount of collagen present in samples and standards.
Finally, after 15 minutes of incubation at room temperature
100μl of Stop Solution was added into each well. The
amount of collagen was quantitated by measuring the absor-
bance (450 nm) using a Tecan GENios Plus microplate
reader (Tecan, Switzerland). Accurate concentrations of col-
lagen in the samples were determined by comparing their
specific absorbances with those obtained for the standards
plotted on a standard curve. Results were expressed as a
means± SD of ng/ml collagen.
2.6. Determination of Cell Proliferation. Cell proliferation was
assessed by using a chemiluminescent immunoassay method,
which is based on the measurement of BrdU incorporation
during DNA synthesis (Roche, CH). When cells are pulsed
with BrdU, it is incorporated into newly synthesized DNA
strands of actively proliferating cells. The incorporation of
BrdU into cellular DNA can be detected using anti-BrdU
antibodies, allowing assessment of the population of cells
synthesizing DNA. Subconfluent cells were treated for 48
with 10% (v/v) of serum from different subjects, and BrdU
was added 12 hrs before the end of the experiments. After
that, the culture supernatant was removed, and the cells were
fixed with a Fix-Denat solution for 30min. The Fix-Denat
was discarded and cells were incubated with an anti-BrdU
antibody conjugated to horseradish peroxidase (anti-BrdU-
POD) for 90min. After rinsing three times with washing
buffer, the substrate solution was added and allowed to react
for 3–10min at room temperature. Within this time window,
the horseradish peroxidase catalyzes the oxidation of diacyl
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hydrazide, where the reaction product decaying from its
excited state yields light. Finally, light emission was read by
using a GENios Plus microplate reader (Tecan). Results were
expressed as a means± SD of the relative light units/sec
(RLU/s) values [25, 26].
2.7. Statistical Analysis. Data were checked for normal distri-
bution and processed by one-way analysis of variance
(ANOVA) followed by post hoc Tukey’s multiple compari-
son tests to determine the differences between mean values
among data groups, with significance defined as P < 0 05.
All the analyses were performed using the GraphPad Prism
6 software (GraphPad Software Inc., San Diego, CA, USA).
3. Results and Discussion
IPF patients enrolled in the study were predominantly males
(72.72%) and had an average age of 71.27± 5.5 years
(Table 1). At baseline (T0), patients had the following spi-
rometry values: FVC was 81.04± 26.95% of the predicted
value and DLCO was 54.17± 18.11% of the predicted value.
After completion of the 24-week treatment period (T1), the
mean FVC was 77.90± 24.49% of the predicted value and
DLCO was 56.1± 22.38% (Table 1). Interestingly, contrary
to data in the literature were IPF-untreated patients were
reported to have shown a functional decline of about
120ml at 24 weeks [23], our Pirfenidone-treated patients
did not show any significant functional decline in terms of
both FVC (P = 0 1813) and DLCO (P = 0 5770).
Intracellular ROS levels were kinetically determined in a
5-hour time-course (Figure 1(a)) and values at 2 hours
(steady state) were used for comparison (Figure 2(a)). Sera
from IPF patients significantly increased intracellular ROS
levels in HPASMCs compared with HD sera (Figure 2(a)).
IPF-induced increase of intracellular ROS was significantly
blunted by the broad NADPH oxidase inhibitor diphenyle-
neiodonium (DPI) [27] suggesting the involvement of the
NOX family of ROS-generating enzymes in the observed
surge of ROS (Figure 2(b)). As with DPI, the exposition
HPASMCs to sera of Pirfenidone-treated IPF (IPF+D)
patients significantly reduced the generation of intracellular
of ROS elicited by IPF sera, indicating the strong antioxidant
potential of this compound (Figure 2(a)).
Exposure of HPASMCs to IPF sera also resulted in a
progressive time-dependent increase of the collagen type
1 (COL1) promoter activity (Figure 1(b)) with values at
8 hours (steady state) significantly higher in cells exposed
to IPF sera compared to HD sera (Figure 3(a)). Also in this
case, the IPF-induced increase of COL1 protein expression
was significantly blunted by DPI suggesting the involve-
ment of NOX-derived ROS in the observed phenomena
(Figure 3(b)). Noteworthy, similar to that observed for the
ROS levels
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Figure 1: (a-b) Real-time assessment of intracellular ROS production and collagen I synthesis in HPASMCs exposed to sera of IPF patients.
(a) Before stimulation, subconfluent human pulmonary artery smooth muscle cells (HPASMCs) were loaded with 10μM of H2-DCFDA and
then cultured in basal medium containing 10% (v/v) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis
patients treated for 24 weeks with Pirfenidone (IPF +D), and healthy donors (HD). Variations in intracellular ROS levels were kinetically
determined in a 5-hour time-course (a randomly selected representative experiment is reported) and values at 2 hours (steady state) were
used in the future comparisons. Fluorescence data were normalized for protein content and expressed as relative fluorescence units
(RFUs). (b) Before stimulation, subconfluent HPASMCs were transduced with lentiviral particles obtained from the COL1A1-LV-tGFP
and EF1α-LV-FP602 lentivectors and then cultured in basal medium containing 10% (v/v) of sera from idiopathic pulmonary fibrosis
(IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF +D), and healthy donors (HD).
Variations of COL1 promoter activation were kinetically followed for 10 hours (a randomly selected representative experiment is
reported) and values at 8 hours (steady state) were used in the future comparison. Data are normalized for transduction efficiency by
reporting the ratio of COL1A1-LV-tGFP to EF1α-LV-FP602 relative fluorescence units (RFUs).
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ROS levels, the IPF-induced increase of COL1 synthesis was
significantly attenuated when HPASMCs were exposed to
sera of IPF patients treated with Pirfenidone (Figure 3(a)).
Data in Figure 4(a) further confirms the ability of IPF
sera to elicit a HPASMC phenotypic switch in terms of
increased cell proliferation, as well as the involvement of
NOX-derived ROS in this phenomenon (Figure 4(b)). In
addition, as previously observed for both ROS and collagen
type 1, Pirfenidone significantly blunted the IPF-elicited
increase of HPASMC proliferation suggesting its ability in
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Figure 2: (a-b) Effects of IPF sera on HPASMC intracellular ROS levels. Before stimulation, subconfluent human pulmonary artery smooth
muscle cells (HPASMCs) were loaded with 10μMof H2-DCFDA, then cultured in basal medium containing 10% (v/v) of sera from idiopathic
pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF +D), and healthy
donors (HD). (b) In selected experiments, cells were pretreated for 60min with the NADPH oxidase inhibitor diphenyleneiodonium
(DPI) before exposure to the sera. (a-b) Data represent the variations of intracellular ROS levels after 2 hours of sera stimulation.
Fluorescence data were normalized for protein content and expressed as relative fluorescence units (RFUs). P value indicating that the
significance is reported in the figure.
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Figure 3: (a-b) Effects of IPF sera on HPASMC collagen I production. (a) Before stimulation, subconfluent HPASMCs were transduced with
lentiviral particles obtained from the COL1A1-LV-tGFP and EF1α-LV-FP602 lentivectors and then cultured in basal medium containing 10%
(v/v) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone
(IPF +D), and healthy donors (HD). Data represent the collagen I promoter activity after 8 hours of sera stimulation. Data are normalized for
transduction efficiency by reporting the ratio of COL1A1-LV-tGFP to EF1α-LV-FP602 relative fluorescence units (RFUs). (b) Subconfluent
HPASMCs were stimulated for 48 hrs with basal medium containing 10% (v/v) of sera from idiopathic pulmonary fibrosis (IPF), sera from
idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF +D), and healthy donors (HD) and processed for
collagen I quantification as reported in the Materials and Methods. In selected experiments, cells were pretreated for 60min with the
NADPH oxidase inhibitor diphenyleneiodonium (DPI) before exposure to the sera. Data are expressed as ng/ml collagen protein. P value
indicating that the significance is reported in the figure.
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counteracting cell function alterations elicited by prooxidant
compounds present in IPF sera. Taken together, the current
finding suggest that (i) phenotypic switching and collagen
synthesis activation in HPASMCs may be driven by IPF sera
in a ROS-dependent fashion, and that (ii) the antioxidant
property of Pirfenidone may be mechanistically responsible
for the observed in vivo antifibrotic effect.
Vascular remodeling in IPF fibrosis is a controversial area
of research. It has now been reported that both areas with
increased angiogenesis and fibrosis are present in the lungs
of patients with this disease, clearly indicating aberrant
microvascular tissue remodeling [28]. Indeed, many different
growth factors and fibrotic mediators are released during the
onset and progression of IPF, including platelet-derived
growth factor (PDGF), transforming growth factor-beta 1
(TGF-β1), tumor necrosis factor-alpha (TNF-α), and vascu-
lar endothelial growth factor (VEGF) [2, 3], which play a piv-
otal role in the promotion of HPASMC phenotypic
switching, proliferation, and eventually extracellular matrix
remodeling [29–32]. TGF-β1 for instance, can exert its profi-
brotic effect via a NADPH oxidase-dependent increase of
intracellular ROS levels [33]. In the lung, NADPH/NOX4-
derived ROS can prompt myofibroblast activation and fibro-
genic response [34]. Consistently, the expression of NADPH/
NOX4 has been reportedly increased in thickened pulmo-
nary arteries of IPF patients [6] and in pulmonary fibroblasts
from IPF patients where it mediates the TGF-β1-induced dif-
ferentiation of fibroblasts into myofibroblasts [35]. Finally, in
consonance with our findings, the inhibition of NOX4 by
pharmacological means reduces lung fibrosis in a rodent dis-
ease model [36].
4. Conclusion
This preliminary pilot study provides new evidence support-
ing the possibility that pathological tissue restructuring in the
lung of IPF patients may be driven and/or maintained by
prooxidant circulating factors acting, at least in part, through
the induction of HPASMC proliferation and the activation of
collagen synthesis. While more studies are needed to pre-
cisely identify both the mediators and the molecular determi-
nants of these effects, our data provide new clues concerning
the mechanism of action of Pirfenidone and indicate a ratio-
nale for considering antioxidant therapies in the treatment or
prevention of IPF.
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Figure 4: (a-b) Effects of IPF sera on HPASMC proliferation. Subconfluent HPASMCs were cultured for 48 hours in basal medium
containing 10% (v/v) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24
weeks with Pirfenidone (IPF +D), and healthy donors (HD). In selected experiments, cells were pretreated for 60min with the NADPH
oxidase inhibitor diphenyleneiodonium (DPI) before exposure to the sera. Data are expressed as ng/ml collagen protein. (a-b) Data are
expressed as relative light units/sec (RLU/s). P value indicating that the significance is reported in the figure.
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